bioAffinity presents positive data on sputum diagnostics to match asthma/COPD patients with therapies

bioAffinity Technologies, Inc.

Poster presented at AAAAI 2026 annual meeting on March 1, 2026, reports ability to identify antibody drug receptors in sputum.
Technology detected receptors for dupilumab and benralizumab, leading asthma/COPD therapies.
Company leveraging CyPath® Lung flow cytometry and AI platform for new asthma/COPD diagnostic tests.
CyPath® Lung commercial test has 92% sensitivity, 87% specificity for early-stage lung cancer detection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.